Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

46.51 -2.35 (-4.81%)
Streaming Delayed Price Updated: 9:43 AM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
40 41 Next >
Michael Burry Says 2022 Is a ‘Plane Crash.’ Here’s What the Legendary Investor Is Betting On.
Michael Burry is back on Twitter, although his first tweet upon his return is not very supportive of current market conditions. 
Via InvestorPlace
Pfizer's Nearly $7 Billion Acquisition Of Arena Pharma Just Paid Off In A Big Way
The company is planning to soon ask for FDA approval of etrasimod in ulcerative colitis. 
Via Investor's Business Daily
Analyzing Bristol-Myers Squibb's Short Interest
Bristol-Myers Squibb's (NYSE:BMY) short percent of float has fallen 10.76% since its last report. The company recently reported that it has 42.24 million shares sold short, which... 
Via Benzinga
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support. 
Via Benzinga
Bristol Myers Q1 Earnings Surpass Street Expectations, Lowers FY22 Guidance
Via Benzinga
Legendary Investor Michael Burry Is Betting Against Apple (AAPL) Stock
Dr. Michael Burry, who earned millions by betting against the housing market in 2008, has a new short position. This time it's on AAPL stock. 
Via InvestorPlace
9 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Jazz Pharmaceuticals Stock Sees Rising Price Performance With Jump To 81 RS Rating
Jazz Pharmaceuticals sees its Relative Strength Rating move into the 80-plus level. 
Via Investor's Business Daily
Looking At Bristol-Myers Squibb's Recent Whale Trades
A whale with a lot of money to spend has taken a noticeably bullish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 14 strange trades. 
Via Benzinga
7 ETFs to Pick-Up From the Tech Wreck
ETFs are a great way to use the current downturn in technology stocks to take advantage of long-term bargains. 
Via InvestorPlace
Michael Burry Is Betting Against Apple: Here's The Size Of 'The Big Short' Investor's Stake
Michael Burry has been known to take large positions against companies he thinks are overvalued. 
Via Benzinga
Warren Buffett Stocks: Berkshire Hathaway Goes On Offense In Stock Market, Adds More Apple
Buffett's Berkshire added to Apple and Chevron during the Q1 sell-off. More details to come. 
Via Investor's Business Daily
Large Cap Biopharmaceuticals: Provide Growth, Value And Yield
Now that all major biopharmaceutical earnings are in, we can review the financial metrics and see if our portfolio needs re-balancing. 
Via Talk Markets
The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology
Via Benzinga
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Top 10 Stocks Helping Warren Buffett Beat the Market
These Warren Buffett stocks are helping the Oracle of Omaha be a winner even in a down market. All are generating solid returns in 2022. 
Via InvestorPlace
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Bristol-Myers: "Boring Is Good"
The firm’s big money-making drug, Revlimid (acquired when it bought Celgene a few years back), which treats a cancer of plasma cells called multiple myeloma, is facing increasing generic competition. 
Via Talk Markets
9 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Peering Into Bristol-Myers Squibb's Recent Short Interest
Bristol-Myers Squibb's (NYSE:BMY) short percent of float has fallen 8.23% since its last report. The company recently reported that it has 47.34 million shares sold short, which... 
Via Benzinga
Check Out What Whales Are Doing With BMY
Someone with a lot of money to spend has taken a bullish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
Bristol-Myers Squibb's Return On Capital Employed Overview
According to Benzinga Pro, during Q1, Bristol-Myers Squibb (NYSE:BMY) earned $1.28 billion, a 45.91% increase from the preceding quarter. Bristol-Myers Squibb's sales decreased to $11.65 billion, a... 
Via Benzinga
What 4 Analyst Ratings Have To Say About Bristol-Myers Squibb
Bristol-Myers Squibb (NYSE:BMY) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
The month of April was a mixed one for regulatory approvals. The Food and Drug Administration delayed approvals for at least three treatment candidates. New molecular entity, or NME, approvals, a... 
Via Benzinga
Week In Review: I-Mab Files For Hong Kong SPAC IPO To Acquire Life Science Company
I-Mab and one of its investors, VMS, have filed for a Hong Kong IPO of a SPAC that will raise funds to acquire a life science company. Also, RVAC Medicines completed a Series B funding that brings... 
Via Talk Markets
Stock Market Volatile; Apple, Facebook, Amazon Are Key Earnings, Tesla CEO Elon Musk Buys Twitter: Weekly Review
The Nasdaq hit its lowest level since 2020. Apple and Facebook led key earnings. 
Via Investor's Business Daily
The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Bristol Myers Squibb Dives As Generics, Revlimid Rivals Slam 2022 Outlook
Bristol Myers' 2022 outlook sustained deep cuts Friday as generics eat away at its biggest products. 
Via Investor's Business Daily
Bristol-Myers Squibb: Q1 Earnings Insights
Bristol-Myers Squibb (NYSE:BMY) reported its Q1 earnings results on Friday, April 29, 2022 at 06:59 AM. Here's what investors need to know about the announcement. 
Via Benzinga
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
40 41 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.